lung cancer | |||||||
新闻 | |||||||
Clinical Implications of Real-World Amivantamab Data in NSCLC - Cancer Network Lung cancer experts discuss how these real-world data comparing amivantamab with alternative therapies may impact their clinical practice.
| |||||||
why different cancers require different treatments, and how evolution drives drug resistance Understanding how cancer cells evolve could help researchers develop more effective ... In contrast, BRAF mutations are rare in lung cancer.
| |||||||
Kiromic BioPharma Announces FDA Authorization of IND to Initiate Phase 1 Clinical Trial ... Each year, more people die of lung cancer than of colon, breast, and prostate cancers combined. "Receiving the authorization from the FDA to ...
| |||||||
Advancements in EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) Pipeline The leading EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) Companies include Dizal Pharmaceuticals, Novartis Pharmaceuticals, AstraZeneca, Betta ...
| |||||||
Immunoprofiling to decode the humoral immune response - News Medical Chronic diseases, such as cancer, neurological and autoimmune diseases, ... an antibody screen on a non-small cell lung cancer patient group.
| |||||||
Biden to Pick Monica Bertagnolli as Director of National Institutes of Health The American Cancer Society and ACS CAN applaud the report. Bertagnolli, an oncologist, has been running the National Cancer Institute.
| |||||||
Immutep Receives Approval to Initiate INSIGHT-005 Trial Evaluating Eftilagimod Alpha and ... Urothelial carcinoma is the most common type of bladder cancer. ... for a variety of solid tumours including non-small cell lung cancer (NSCLC), ...
| |||||||
查看更多结果 | 修改此快讯 |
您收到此电子邮件是因为您订阅了Google快讯。 |
以RSS Feed的形式接收此快讯 |
发送反馈 |
No comments:
Post a Comment